Two key U.S. congressional committee members on Friday called for an investigation into whether Mylan NV, under fire for raising the price of its EpiPen device, overcharged the government's low-income healthcare program for the allergy treatment. In a letter to the secretary of the Department of Health and Human Services, Senator Ron Wyden and Representative Frank Pallone, both Democrats, seek clarification of whether EpiPen was classified as a generic, “non-innovator” drug, or a brand-name drug by the Medicaid program. Under current law, branded drugs, and generic drugs available from a single source, are required to pay a rebate amount of at least 23.1 percent of the average manufacturer price.
More here:
U.S. lawmakers question Mylan’s Medicaid EpiPen rebates